BeiGene (BSP:B1GN34) Total Equity : R$16,734 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is BeiGene Total Equity?

BeiGene's total equity for the quarter that ended in Mar. 2024 was R$16,734 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

BeiGene Total Equity Historical Data

The historical data trend for BeiGene's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Total Equity Chart

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Equity

Get a 7-Day Free Trial

4,015.66

19,906.09

34,679.03

22,992.45

17,332.20

BeiGene Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Equity	Get a 7-Day Free Trial															21,653.74	18,437.07	18,585.48	17,332.20	16,733.93

BeiGene Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

BeiGene's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	28444.686	-	11112.492
	=	17,332

BeiGene's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity	=	Total Assets(Q: Mar. 2024 )	-	Total Liabilities(Q: Mar. 2024 )
	=	28223.918	-	11489.992
	=	16,734

BeiGene Total Equity Related Terms

Thank you for viewing the detailed overview of BeiGene's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (BSP:B1GN34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (BSP:B1GN34) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

BGNE:USA 06160:Hong Kong 49BA:Germany 688235:China

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (BSP:B1GN34) Headlines

No Headlines